Effect of Asfotase Alfa on Muscle Weakness in a Japanese Adult Patient of Hypophosphatasia with Low ALP Levels

Intern Med. 2020 Mar 15;59(6):811-815. doi: 10.2169/internalmedicine.3298-19. Epub 2019 Nov 29.

Abstract

A 40-year-old Japanese woman presented to our hospital with general fatigue and muscle weakness. She had a history of premature loss of deciduous teeth at 4 years old, her serum alkaline phosphatase (ALP) activity was as low as 91 U/L, and radiologic studies revealed thoracic deformity and sacroiliac calcification. Genetic sequencing revealed a heterozygous c.1559delT mutation in the tissue non-specific alkaline phosphatase gene (ALPL). Based on these findings, she was diagnosed with hypophosphatasia (HPP), and treatment with asfotase alfa, a recombinant human tissue-nonspecific alkaline phosphatase (TNSALP), was initiated. After six months of treatment with asfotase alfa, improvements were observed in the SF-36 score, six-minute walk distance, and grasping power. Although the overdiagnosis needs to be avoided, HPP should be considered in patients with undiagnosed musculoskeletal symptoms and a low serum ALP activity.

Keywords: alkaline phosphatase; asfotase alfa; bone metabolism; hypophosphatasia.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Alkaline Phosphatase / genetics
  • Alkaline Phosphatase / therapeutic use*
  • Enzyme Replacement Therapy / methods*
  • Female
  • Hand Strength
  • Humans
  • Hypophosphatasia / diagnosis*
  • Hypophosphatasia / drug therapy*
  • Hypophosphatasia / genetics
  • Immunoglobulin G / therapeutic use*
  • Japan
  • Muscle Fatigue / drug effects*
  • Muscle Weakness / drug therapy
  • Recombinant Fusion Proteins / therapeutic use*
  • Walk Test

Substances

  • Immunoglobulin G
  • Recombinant Fusion Proteins
  • ALPL protein, human
  • Alkaline Phosphatase
  • asfotase alfa